Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

It is important for achieving complete remission of acute myelogenous leukemia to manage anemia and bone marrow hypoplasia, which cause serious complications. Anemia and bone marrow hypoplasia are mainly treated by supportive therapies consisting of granulocyte-colony stimulating factor, red blood cell transfusion and platelet transfusion, which are given according to recommendations of guidelines. In addition to these supportive therapies, new drugs such as DNA demethylating agents are developed for myelodysplastic syndrome (MDS). These drugs are expected to improve a cytopenia, and reduce the frequency of transfusions.

Original languageEnglish
Pages (from-to)1974-1977
Number of pages4
JournalNippon rinsho. Japanese journal of clinical medicine
Volume67
Issue number10
Publication statusPublished - 2009 Oct

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this